Roche Pitches in on Regeneron’s COVID-19 Antibody Combination

Swiss pharma giant Roche announced that it is partnering with Regeneron Pharmaceuticals to ramp up production of the New York-based biotech’s COVID-19 antibody cocktail candidate, REGN-COV2.

Under the deal, the two companies will dedicate annual manufacturing capacity for the double-antibody combination, and they expect to increase capacity “to at least three-and-a-half times the current capacity, with the potential for even further expansion,” Roche said.

As part of the agreement, Roche will handle worldwide distribution outside the U.S. if the two-antibody combination gets regulatory approval.